FCM
NVET

Farallon Capital Management’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Farallon Capital Management’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,648,696
Closed -$17.7M – 105
2017
Q2 		$17.7M Hold
2,648,696
– – 0.18% 58
2017
Q1 		$10.3M Hold
2,648,696
– – 0.11% 61
2016
Q4 		$9.72M Hold
2,648,696
– – 0.11% 58
2016
Q3 		$11M Hold
2,648,696
– – 0.16% 49
2016
Q2 		$12.3M Hold
2,648,696
– – 0.17% 47
2016
Q1 		$8.74M Buy
2,648,696
+145,000
+6% +$473K 0.08% 60
2015
Q4 		$8.54M Hold
2,503,696
– – 0.08% 55
2015
Q3 		$9.11M Buy
2,503,696
+3,700
+0.1% +$16.9K 0.12% 60
2015
Q2 		$12.4M Hold
2,499,996
– – 0.17% 62
2015
Q1 		$20.1M Buy
+2,499,996
New +$23.7M 0.29% 55

Farallon Capital Management's NVET Position: Q3 2017 in Review

Farallon Capital Management sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q3 2017, closing a stake of 2,648,696 shares — an estimated $17.7M sold.

Farallon Capital Management first reported a position in NVET in Q1 2015 and held it in 10 quarters. The position peaked at $20.1M in Q1 2015. 0 funds tracked by Wall St. Rank hold NVET as of Q3 2017.

  • Farallon Capital Management reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Farallon Capital Management sold 2,648,696 Nexvet Biopharma plc Ordinary Shares shares in Q3 2017, an estimated $17.7M.
  • Farallon Capital Management first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 10 quarters.
  • Farallon Capital Management's Nexvet Biopharma plc Ordinary Shares position peaked at $20.1M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q3 2017.

Based on Farallon Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.